CLAIM CARD
Within the corpus, notable tensions exist regarding the magnitude and consistency of CoQ10's anti-inflammatory effects across different study contexts. The Zhai 2017 systematic review reported unclear overall direction of effect on inflammatory markers, while Jorat 2019 in coronary artery disease found consistent significant reductions across multiple biomarkers. Furthermore, Alehagen 2022b's analysis of a selenium and CoQ10 intervention trial reported null findings for certain immune-related biomarkers (P < 0.001 for some endpoints but with a reported null overall effect direction), creating tension with the positive signal from Dahri 2019. The retracted PCOS study by Rahmani 2018 reported improvements in gene expression related to inflammation, adding further heterogeneity to the evidence base.
Evidence grade: exploratory
Contradiction status: none
Publication: b8dee5f7-0023-4af5-bacc-446de915555a
Provenance: Derivation Web chain
Citation Support
source_1Xu 2024source_2Spiegeleer 2025source_3Shang 2024source_4Alehagen 2020source_5Phan 2020